Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from cardiovascular disease (CVD), which accounts for >50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD compared with the general population. The results from mandatory cardiovascular outcome trials (CVOTs) are therefore of great interest in the field. The Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes meeting program aims to bring together experts from several associated disciplines to provide fair and balanced resources for those involved in the management of patients with T2D. This publication represents the opinions of the faculty on the key learnings from the meeting held in Vienna in the spring of 2017. In particular, we detail how data from the EMPA-REG OUTCOME® [cardiovascular outcomes trial of empagliflozin] and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®) (liraglutide) CVOTs can be practically interpreted across clinical specialities. It is hoped that this translation of CVOT data will achieve a dual treatment paradigm for the management of both raised glucose levels and CV risk in patients with T2D.

Cardiovascular Division Hadassah Medical Centre Jerusalem Israel

Charles University Prague Czech Republic

Department of Medicine 1 Rudolfstiftung Hospital Vienna Austria

Diabetes Research Centre Leicester General Hospital Leicester UK

Division of Nephrology and Hypertension Consultation University Hospital of Lausanne Lausanne Switzerland

Vorarlberg Institute for Vascular Investigation and Treatment Feldkirch Austria

Zobrazit více v PubMed

International Diabetes Federation IDF Diabetes Atlas. 7th ed. 2015. [Accessed October 10, 2017]. pp. 1–140. Available from: http://www.diabetesatlas.org/

Seshasai SRK, Kaptoge S, Thompson A, et al. Emerging Risk Factors Collaboration Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–841. PubMed PMC

Schernthaner G, Jarvis S, Lotan C, Prázný M, Wanner C, Wascher TC. Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. Ther Clin Risk Manag. 2017;13:69–79. PubMed PMC

Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) Cardiovasc Diabetol. 2014;13(1):102. PubMed PMC

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. PubMed PMC

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. PubMed

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. PubMed

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. PubMed

Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. PubMed

Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med. 2010;123(4):374. PubMed

UKPDS Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352(9131):837–853. PubMed

Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–2206. PubMed

Ismail-Beigi F, Genuth S. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012;97(1):41–48. PubMed

Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. PubMed PMC

Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392–1406. PubMed

Dalrymple LS, Katz R, Kestenbaum B, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011;26(4):379–385. PubMed PMC

Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539. PubMed

Wakisaka M. Letter to the editor on: Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):1799–1802. PubMed

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. PubMed

Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526–1534. PubMed PMC

Jardiance 10 mg and 25 mg film-coated tablets [prescribing information]. (eMC) Print friendly, 2017. Germany: Boehringer Ingelheim Limited;

Jardiance [prescribing information] Ingelheim am Rhein. Germany: Boehringer Ingelheim International GmbH; 2016. pp. 1–34.

Lehmann R, Bianda T, Brändle M, et al. Mesures Visant Contrôle De La Glycémie Chez Les Patients Atteints De Diabète Sucré De Type 2. [Recommendations of SGED/SSED: Measures for blood glucose control in patients with type 2 diabetes mellitus] Baden: Société Suisse d’Endocrinologie et de Diabétologie; 2016. [Accessed October 10, 2017]. pp. 1–17. French. Available from: http://sgedssed.ch/fr/informations-pour-professionnels/lignes-directrices/

Lehmann R, Bianda T, Brändle M, et al. Empfehlungen der SGED/SSED: Massnahmen zur Blutzuckerkontrolle bei Patienten mit Diabetes mellitus Typ 2. [Recommendations of SGED/SSED: Measures for blood glucose control in patients with type 2 diabetes mellitus] Baden: Schweizerische Gesellschaft für Endokrinologie und Diabetologie; 2016. [Accessed October 10, 2017]. pp. 1–16. German. Available from: http://sgedssed.ch/informationen-fuer-fachpersonen/richtlinien-guidelines/

Škrha J, Pelikánová T, Kvapil M. Czech Diabetes Society Recommended treatment for type 2 diabetes mellitus. Prague: 2016. Česká diabetologická společnost; pp. 1–15. Czech.

Austrian Diabetes Society (ODG) and the Austrian Lipid Consensus Co-ordinated by Clodi M. and Toplak H. Diabetes mellitus – Instructions for practice. Revised and extended version 2016. Wiener klinische wochenschrift. The Central European Journal of Medicine. 2016;128:S37–S228. German.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes. 2016;40(6):484–486. PubMed

Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2017;20(1S):1–121.

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–2381. PubMed PMC

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200. PubMed

Roffi M, Patrono C, Collet J-P, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) Eur Heart J. 2016;37(3):267–315. PubMed

FDA FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015. [Accessed April 27, 2017]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm.

PRAC, Committee PRA PRAC recommendation, EMA/76661/2017. 2017. [Accessed April 27, 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_Canagliflozin_20/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500221431.pdf.

Kohler S, Patel S, DeFronzo RA, et al. Safety and tolerability of combinations of empagliflozin/linagliptin for 52 weeks in subjects with type 2 diabetes. 2015. [Accessed October 10, 2017]. Available from: http://www.easdvirtualmeeting.org/resources/safety-and-tolerability-of-combinations-of-empagliflozin-linagliptin-for-52-weeks-in-subjects-with-type-2-diabetes--3.

Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care. 2017;40(Suppl 1):S4–S5. PubMed

Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. PubMed

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. PubMed

Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. PubMed

White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. PubMed

Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37. PubMed PMC

Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017 May 18; Epub. PubMed PMC

Nyström T, Bodegård J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2017;35(6):1364. PubMed PMC

Toulis KA, Willis BH, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network database. J Clin Endocrinol Metab. 2017;102(5):1719–1725. PubMed

Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709–717. PubMed

Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–113. PubMed PMC

Scheen AJ. Diabetes: time for reconciliation between cardiologists and diabetologists. Nat Rev Cardiol. 2016;13(9):509–510. PubMed